Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 2-week, randomized, double-blind, placebo-controlled study

This 2-week randomized, double-blind, placebo-controlled fixed-dose study (NCT02919501) explored the potential of accelerating onset of antidepressant efficacy and plasma exposure with single-dose intravenous vortioxetine at oral vortioxetine treatment initiation. Outpatients (ages 18–65 years) with...

Descripción completa

Detalles Bibliográficos
Autores principales: Vieta, Eduard, Florea, Ioana, Schmidt, Simon Nitschky, Areberg, Johan, Ettrup, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams And Wilkins 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587371/
https://www.ncbi.nlm.nih.gov/pubmed/31094901
http://dx.doi.org/10.1097/YIC.0000000000000271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587371/
https://www.ncbi.nlm.nih.gov/pubmed/31094901
http://dx.doi.org/10.1097/YIC.0000000000000271

Ejemplares similares